Clinical Trial

TACE Combined Surgery for the Resectable Huge HCC

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 3, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Huge hepatocellular carcinoma (HCC) is defined as a tumor with a maximum diameter greater than 10 cm. With advancements in surgical techniques, hepatectomy can be performed safely in some patients with huge HCC without vascular invasion or distant metastasis and with preserved liver function. The high risk of recurrence after surgery is another challenge for surgeons. Neoadjuvant TACE has been shown to improve the clinical outcomes of patients with HCC, especially those with a high risk of recurrence, such as those with multinodular tumors, large tumors, and tumor thrombus. The present multicenter study aimed to evaluate the efficacy of neoadjuvant TACE in patients with huge HCC who underwent liver resection.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-21.
Trial Details
NCT Number NCT06898398
Lead Sponsor Sun Yat-sen University
Conditions Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer, Surgery
Enrollment 326 participants
Start Date 2025-01-01
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-03